Difference between revisions of "Juvenile myelomonocytic leukemia"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "(NCT[0-9]{8}) Clinical Trial Registry" to "$1 $1") |
Warner-admin (talk | contribs) m (Text replacement - ", <20 p" to ", fewer than 20 p") |
||
Line 23: | Line 23: | ||
|[http://www.ncbi.nlm.nih.gov/pmc/articles/pmc8341358/ Niemeyer et al. 2021 (AZA-JMML-001)] | |[http://www.ncbi.nlm.nih.gov/pmc/articles/pmc8341358/ Niemeyer et al. 2021 (AZA-JMML-001)] | ||
|2015-2017 | |2015-2017 | ||
− | | style="background-color:#ffffbe" |Phase 2, | + | | style="background-color:#ffffbe" |Phase 2, fewer than 20 pts (RT) |
|- | |- | ||
|} | |} |
Revision as of 07:08, 18 July 2023
1 regimens on this page
1 variants on this page
|
First-line therapy
Azacitidine monotherapy
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Niemeyer et al. 2021 (AZA-JMML-001) | 2015-2017 | Phase 2, fewer than 20 pts (RT) |
References
- AZA-JMML-001: Niemeyer CM, Flotho C, Lipka DB, Starý J, Rössig C, Baruchel A, Klingebiel T, Micalizzi C, Michel G, Nysom K, Rives S, Schmugge Liner M, Zecca M, Schönung M, Baumann I, Nöllke P, Benettaib B, Biserna N, Poon J, Simcock M, Patturajan M, Menezes D, Gaudy A, van den Heuvel-Eibrink MM, Locatelli F. Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial. Blood Adv. 2021 Jul 27;5(14):2901-2908. link to original article link to PMC article PubMed NCT02447666